As well, KEYNOYE‐024 and KEYNOYE‐001 showed that pembrolizumab was associated with significantly superior overall survival (OS) over chemotherapy in patients with advanced NSCLC and PD‐L1 ≥ 50%.5 The gene discussed is CD274; the disease is non-small cell lung carcinoma.